Nasdaq:EFTRUS28202V1089

No Picture
News

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

November 1, 2021 sandiegobiotech Comments Off on eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company’s… Click here to view original post… […]

No Picture
News

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

September 16, 2021 sandiegobiotech Comments Off on eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40… Click here to view original post… […]